Kelly-Hanku Angela, Nightingale Claire Elizabeth, Pham Minh Duc, Mek Agnes, Homiehombo Primrose, Bagita Mary, Nankinga Justine, Vallely Andrew, Vallely Lisa, Sethy Ghanashyan, Kaldor John, Luchters Stanley
The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
Papua New Guinea Institute of Medical Research, Goroka, Eastern Highlands Province, Papua New Guinea.
BMJ Open. 2020 Dec 12;10(12):e038311. doi: 10.1136/bmjopen-2020-038311.
Despite early adoption of the WHO guidelines to deliver lifelong antiretroviral (ARV) regimen to pregnant women on HIV diagnosis, the HIV prevention of mother to child transmission programme in Papua New Guinea remains suboptimal. An unacceptable number of babies are infected with HIV and mothers not retained in treatment. This study aimed to describe the characteristics of this programme and to investigate the factors associated with programme performance outcomes.
We conducted a retrospective analysis of clinical records of HIV-positive pregnant women at two hospitals providing prevention of mother to child transmission services. All women enrolled in the prevention of mother to child transmission programme during the study period (June 2012-June 2015) were eligible for inclusion. Using logistic regression, we examined the factors associated with maternal loss to follow-up (LTFU) before birth and before infant registration in a paediatric ARV programme.
763 of women had records eligible for inclusion. Demographic and clinical differences existed between women at the two sites. Almost half (45.1%) of the women knew their HIV-positive status prior to the current pregnancy. Multivariate analysis showed that women more likely to be LTFU by the time of birth were younger (adjusted OR (AOR)=2.92, 95% CI 1.16 to 7.63), were newly diagnosed with HIV in the current/most recent pregnancy (AOR=3.50, 95% CI 1.62 to 7.59) and were in an HIV serodiscordant relationship (AOR=2.94, 95% CI 1.11 to 7.84). Factors associated with maternal LTFU before infant registration included being primipara at the time of enrolment (AOR=3.13, 95% CI 1.44 to 6.80) and being newly diagnosed in that current/most recent pregnancy (AOR=2.49, 95% CI 1.31 to 4.73). 6.6% (50 of 763) of exposed infants had a positive HIV DNA test.
Our study highlighted predictors of LTFU among women. Understanding these correlates at different stages of the programme offers important insights for targets and timing of greater support for retention in care.
尽管巴布亚新几内亚已尽早采用世界卫生组织的指南,为确诊感染艾滋病毒的孕妇提供终身抗逆转录病毒治疗方案,但该国的预防母婴传播艾滋病毒项目仍未达到最佳效果。有数量多得令人无法接受的婴儿感染了艾滋病毒,而且母亲未坚持接受治疗。本研究旨在描述该项目的特征,并调查与项目实施结果相关的因素。
我们对两家提供预防母婴传播服务的医院中艾滋病毒呈阳性的孕妇的临床记录进行了回顾性分析。在研究期间(2012年6月至2015年6月)参加预防母婴传播项目的所有妇女均符合纳入条件。我们使用逻辑回归分析,研究了与母亲在分娩前以及婴儿在儿科抗逆转录病毒项目中登记前失访相关的因素。
763名妇女的记录符合纳入条件。两家医院的妇女在人口统计学和临床特征方面存在差异。近一半(45.1%)的妇女在本次怀孕前就知道自己艾滋病毒呈阳性。多变量分析显示,到分娩时更有可能失访的妇女年龄较小(调整后的比值比(AOR)=2.92,95%置信区间为1.16至7.63),在本次/最近一次怀孕中新诊断出感染艾滋病毒(AOR=3.50,95%置信区间为1.62至7.59),并且处于艾滋病毒血清学不一致的关系中(AOR=2.94,95%置信区间为1.11至7.84)。与母亲在婴儿登记前失访相关的因素包括在入组时为初产妇(AOR=3.13,95%置信区间为1.44至6.80)以及在本次/最近一次怀孕中新诊断出感染艾滋病毒(AOR=2.49,95%置信区间为1.31至4.73)。6.6%(763名中的50名)暴露婴儿的艾滋病毒DNA检测呈阳性。
我们的研究突出了妇女失访的预测因素。了解项目不同阶段的这些相关因素,可为加大护理留存支持的目标和时机提供重要见解。